HUP0400914A2 - Eljárások mitokondriális betegségek kezelésére - Google Patents

Eljárások mitokondriális betegségek kezelésére

Info

Publication number
HUP0400914A2
HUP0400914A2 HU0400914A HUP0400914A HUP0400914A2 HU P0400914 A2 HUP0400914 A2 HU P0400914A2 HU 0400914 A HU0400914 A HU 0400914A HU P0400914 A HUP0400914 A HU P0400914A HU P0400914 A2 HUP0400914 A2 HU P0400914A2
Authority
HU
Hungary
Prior art keywords
group
hydrogen atom
formula
alkyl
treatment
Prior art date
Application number
HU0400914A
Other languages
English (en)
Inventor
Robert K. Naviaux
Original Assignee
Pro-Neuron, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pro-Neuron, Inc. filed Critical Pro-Neuron, Inc.
Publication of HUP0400914A2 publication Critical patent/HUP0400914A2/hu
Publication of HUP0400914A3 publication Critical patent/HUP0400914A3/hu
Publication of HU230191B1 publication Critical patent/HU230191B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

A találmány tárgya eljárás mitokondriális rendellenességgelkapcsolatos egy vagy több tünet enyhítésére vagy megszüntetésére, amiabból áll, hogy a kezelésre szoruló szervezetbe az (I) általánosképletű - ahol R1 jelentése OH, NHCOCH3 vagy NH2 képletű csoport; R2jelentése hidrogénatom, CO2H képletű csoport vagy -C(=O)O-(CX2)0-21-CX3 (II) általános képletű csoport, melyen belül X jelentése 1-22szénatomos alkil-, 1-22 szénatomos alkenil-, 1-22 szénatomosalkinilcsoport, melyek hidrogénatommal, 1-3 szénatomosalkilcsoporttal, OH, NH2 képletű csoporttal vagy halogénatommalhelyettesítettek; vagy X jelentése hidrogénatom; R3, R4 és R5jelentése egymástól függetlenül hidrogénatom vagy 1-22 szénatomosalkil-karbonil-csoport, mely adott esetben 1-3 szénatomos alkil-, OH,NH2 képletű csoporttal vagy halogénatommal helyettesített; és ahol azR3, R4 és R5 legalább egyikének jelentése nem hidrogénatom - vegyülethatásos mennyiségét juttatják. Ó
HU0400914A 1999-02-23 2000-02-23 Nukleozidok mitokondriális betegségek kezelésére HU230191B1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12158899P 1999-02-23 1999-02-23
US60/121,588 1999-02-23
PCT/US2000/004663 WO2000050043A1 (en) 1999-02-23 2000-02-23 Methods of treatment of mitochondrial disorders

Publications (3)

Publication Number Publication Date
HUP0400914A2 true HUP0400914A2 (hu) 2004-08-30
HUP0400914A3 HUP0400914A3 (en) 2007-05-29
HU230191B1 HU230191B1 (hu) 2015-09-28

Family

ID=22397641

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400914A HU230191B1 (hu) 1999-02-23 2000-02-23 Nukleozidok mitokondriális betegségek kezelésére

Country Status (20)

Country Link
US (2) US7638501B1 (hu)
EP (2) EP1808177B1 (hu)
JP (1) JP4776780B2 (hu)
KR (2) KR100758712B1 (hu)
CN (2) CN100379426C (hu)
AT (1) ATE381935T1 (hu)
AU (1) AU776437B2 (hu)
BR (1) BR0008447A (hu)
CA (1) CA2362925C (hu)
DE (1) DE60037578T2 (hu)
DK (1) DK1171137T3 (hu)
ES (1) ES2298130T3 (hu)
HU (1) HU230191B1 (hu)
IL (3) IL144964A0 (hu)
MX (1) MXPA01008549A (hu)
NZ (1) NZ513926A (hu)
PT (1) PT1171137E (hu)
RU (2) RU2268732C2 (hu)
WO (1) WO2000050043A1 (hu)
ZA (1) ZA200107727B (hu)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306909B1 (en) 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
US8518882B2 (en) * 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US20050203053A1 (en) * 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US8314064B2 (en) * 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
US8143234B2 (en) * 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
DK1870103T3 (da) * 1998-07-31 2010-01-11 Massachusetts Inst Technology Anvendelse af uridin i kombination med cholin i behandling af hukommelsesforsstyrrelse
US7807654B2 (en) 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US7915233B1 (en) 1998-08-31 2011-03-29 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
DE60037578T2 (de) 1999-02-23 2009-01-08 The Regents Of The University Of California, Oakland Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
US6727231B1 (en) * 2000-10-12 2004-04-27 Repligen Corporation Uridine therapy for patients with elevated purine levels
DE10110355A1 (de) * 2001-03-03 2002-09-12 Ulrich Walker Bekämpfung von Nebenwirkungen
CA2444148A1 (en) * 2001-04-11 2002-10-24 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
AU2002302272B2 (en) * 2001-05-29 2008-05-22 The University Of British Columbia Pharmacological applications of mitochondrial DNA assays
JP2004182705A (ja) * 2002-10-11 2004-07-02 Yasutoshi Koga ミトコンドリア機能異常に起因する疾患における臨床症状発現の予防・治療用組成物
KR20050092424A (ko) * 2003-01-17 2005-09-21 씨브이 쎄러퓨틱스, 인코포레이티드 심혈관 질환의 치료에 유용한 치환된 헤테로고리 화합물
DK1888059T3 (en) 2005-06-01 2015-03-30 Edison Pharmaceuticals Inc Redox-active therapeutic products for the treatment of mitochondrial diseases and other conditions as well as modulation of energy biomarkers
US7432305B2 (en) 2005-09-15 2008-10-07 Edison Pharmaceuticals, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
JP5374162B2 (ja) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
US8748405B2 (en) 2007-01-26 2014-06-10 City Of Hope Methods and compositions for the treatment of cancer or other diseases
CN105510850A (zh) 2007-11-02 2016-04-20 麻省理工学院 尿苷饮食添加顺应性方法及其用途
CN101612110B (zh) * 2008-06-23 2012-07-25 欣凯医药化工中间体（上海）有限公司 三乙酰尿苷缓释制剂及其制备方法
WO2010030607A1 (en) 2008-09-10 2010-03-18 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
ES2640485T3 (es) * 2011-08-12 2017-11-03 Universitätsklinikum Freiburg Uridina y análogos de uridina para el uso en el tratamiento de la enfermedad pulmonar obstructiva crónica
WO2015106255A1 (en) 2014-01-13 2015-07-16 City Of Hope Multivalent oligonucleotide assemblies
WO2016028894A1 (en) * 2014-08-19 2016-02-25 Wellstat Therapeutics Corportion Treatment of glycosylation deficiency diseases
FR3027804A1 (fr) * 2014-10-31 2016-05-06 Centre Nat Rech Scient Utilisation d'un inhibiteur de transcriptase inverse dans la prevention et le traitement des maladies degeneratives
US10675293B2 (en) 2015-05-29 2020-06-09 The Board Of Trustees Of The Leland Stanford Junior University Nucleoside agents for the reduction of the deleterious activity of extended nucleotide repeat containing genes
MX2017015566A (es) * 2015-06-05 2018-08-15 Fundacio Hospital Univ Vall Dhebron Institut De Recerca Tratamiento de enfermedades mitocondriales.
RU2721492C2 (ru) * 2015-06-17 2020-05-19 Зе Трастис Оф Коламбия Юниверсити Ин Зе Сити Оф Нью-Йорк Дезоксинуклеозидная терапия заболеваний, вызванных несбалансированными пулами нуклеотидов, в том числе синдромов истощения митохондриальной днк
EP3389646A1 (en) 2015-12-17 2018-10-24 BioElectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
KR101981843B1 (ko) 2016-09-13 2019-05-23 울산대학교 산학협력단 일산화탄소 또는 일산화탄소 공급체를 유효성분으로 함유하는 미토콘드리아 기능 개선용 조성물
CA3094324A1 (en) 2018-03-26 2019-10-03 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
JP2022546611A (ja) * 2019-09-05 2022-11-04 ミトレインボー セラピューティクス，インコーポレーテッド ミトコンドリアｄｎａ枯渇障害の処置
KR102290596B1 (ko) * 2020-09-10 2021-08-19 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 주사용 조성물 및 이의 용도
EP3970713A1 (en) 2020-09-16 2022-03-23 GV Squared S.r.l. Pharmaceutical composition comprising uridine and pyruvate for regulating the profileration, activity and survival of immune cells
CN113116900B (zh) * 2021-04-14 2022-07-08 兰州大学 一类核苷类似物在制备预防和/或治疗脑血管疾病药物中的应用
BE1030026B1 (fr) * 2022-06-14 2023-07-07 Dendrogenix Composés dérivés de stérols et composition pharmaceutique les comprenant pour leur utilisation dans la prévention, l’amélioration et/ou le traitement d’une pathologie liée à un déficit mitochondrial

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5356690A (en) * 1976-09-30 1978-05-23 Rikagaku Kenkyusho Purin compund sugar derivatives and their preparation
US6348451B1 (en) 1987-10-28 2002-02-19 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
US6060459A (en) 1987-10-28 2000-05-09 Pro-Neuron, Inc. Enhancing blood cell count with oxypurine nucleosides
US5691320A (en) 1987-10-28 1997-11-25 Pro-Neuron, Inc. Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis
CA1321994C (en) * 1987-10-28 1993-09-07 Reid Von Borstel Acylated uridine and cytidine and uses thereof
US5736531A (en) 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US6020322A (en) 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
US5470838A (en) 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US6329350B1 (en) 1987-10-28 2001-12-11 Pro-Neuron, Inc. Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
ATE142221T1 (de) 1987-10-28 1996-09-15 Pro Neuron Inc Acyl deoxyribonukleosid-derivate und deren verwendungen
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US6743782B1 (en) 1987-10-28 2004-06-01 Wellstat Therapeutics Corporation Acyl deoxyribonucleoside derivatives and uses thereof
IT1219667B (it) 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
IT1241984B (it) 1990-06-13 1994-02-02 Polifarma Spa Impiego di uridina nel trattamento farmacologico delle complicazioni periferiche del diabete
US5981601A (en) * 1992-05-28 1999-11-09 Centre For Molecular Biology And Medicine Method for enhancing cellular bioenergy
US5567689A (en) 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
US5852000A (en) 1993-08-25 1998-12-22 Otsuka Pharmaceutical Factory, Inc. Cardiac rehabilitation agent
BR9507241A (pt) * 1994-03-30 1997-09-16 Mitokor Processos para detectar a presença de doença de alzheimer e de origem mitocondrial em um indivíduo e as mutações genéticas que provocam doença de alzheimer para inibir a transcrição ou tradução de genes e de um ou mais ácidos nucleicos codificando oxidase de citocromo c mutante para introduzir seletivamente uma molécula conjugada em mitocôndrias para construir uma linhagem de células para avaliar um composto para utilidade em potencial no diagnóstico de distúrbios no tratamento de um distúrbio eno diagnóstico ou tratamento de diabetes mellitus para preparar um animal cibrido e para determinar a presença de uma doença humana de origem mitoconddrial sequências de nucleotideos isoladas sonda kit composição terapêutica ribozima linhagem de cêlulas e animal cibrido
JP3808121B2 (ja) * 1995-01-09 2006-08-09 日本メジフィジックス株式会社 低酸素症またはミトコンドリア機能障害診断剤
US5962459A (en) 1996-05-28 1999-10-05 Polifarma S.P.A. Therapeutic active agent for treatment of neuron degenerative diseases
JPH10273469A (ja) * 1997-02-03 1998-10-13 Takeda Chem Ind Ltd ２環性キノン誘導体、製造法および剤
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US7807654B2 (en) 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
DE60037578T2 (de) 1999-02-23 2009-01-08 The Regents Of The University Of California, Oakland Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen

Also Published As

Publication number Publication date
RU2005121711A (ru) 2007-01-20
JP2002537340A (ja) 2002-11-05
KR20020031331A (ko) 2002-05-01
KR100758712B1 (ko) 2007-09-14
EP1808177A2 (en) 2007-07-18
KR20070085864A (ko) 2007-08-27
HUP0400914A3 (en) 2007-05-29
BR0008447A (pt) 2002-01-15
CN1191835C (zh) 2005-03-09
ES2298130T3 (es) 2008-05-16
DE60037578T2 (de) 2009-01-08
DK1171137T3 (da) 2008-03-31
ATE381935T1 (de) 2008-01-15
KR100879559B1 (ko) 2009-01-22
AU776437B2 (en) 2004-09-09
EP1171137A4 (en) 2004-04-07
WO2000050043A1 (en) 2000-08-31
IL144964A0 (en) 2002-06-30
CA2362925C (en) 2011-04-12
US7638501B1 (en) 2009-12-29
NZ513926A (en) 2001-09-28
EP1171137B1 (en) 2007-12-26
MXPA01008549A (es) 2003-06-06
CN1341024A (zh) 2002-03-20
RU2268732C2 (ru) 2006-01-27
PT1171137E (pt) 2008-03-17
AU3243400A (en) 2000-09-14
EP1808177A3 (en) 2010-07-28
CN100379426C (zh) 2008-04-09
JP4776780B2 (ja) 2011-09-21
US8748408B2 (en) 2014-06-10
DE60037578D1 (de) 2008-02-07
RU2394580C2 (ru) 2010-07-20
IL144964A (en) 2013-11-28
EP1808177B1 (en) 2018-08-08
HU230191B1 (hu) 2015-09-28
IL180528A (en) 2013-11-28
US20100098678A1 (en) 2010-04-22
EP1171137A1 (en) 2002-01-16
RU2001125913A (ru) 2005-02-20
AU2004235661A1 (en) 2005-01-27
ZA200107727B (en) 2007-10-31
CN1626107A (zh) 2005-06-15
IL180528A0 (en) 2007-06-03
CA2362925A1 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
HUP0400914A2 (hu) Eljárások mitokondriális betegségek kezelésére
DE69629238D1 (de) Vorrichtung zur Behandlung des Atemstillstands im Schlaf durch Elektrostimulation
DE69535686D1 (de) Vorrichtung zur synchronen Behandlung von obstruktiver Schlafapnoe
ATE336239T1 (de) Neue fettsäureanaloge zur behandlung des bluthochdrucks
DE60116313D1 (de) Verbindungen zur behandlung der alzheimerischen krankheit
ATE312202T1 (de) Menschliche rnase h und entsprechende oligonukleotidverbindungen
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE60220422D1 (de) Substituierte pyrazoloverbindungen zur behandlung von entzündungen
DK0867184T3 (da) Anvendelse af tiagabin til behandling af søvnforstyrrelser
DE60114002D1 (de) VERFAHREN ZUR HERSTELLUNG KRISTALLINEr PARTIKEL ZUR INHALATION
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
DE69401119T2 (de) Vorrichtung zur verhinderung des zähneknirschens
RS38404A (en) Lipoxin a4 analogs
IL160045A0 (en) Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
HUP0104339A2 (hu) Eljárás porckárosodások kezelésére
DE69715686D1 (de) Bakterizide oberfläche
HUP0101258A2 (hu) Helyettesített bisz-indolil-maleimidek, sejtburjánzás gátlására történő felhasználásra
DK0865271T4 (da) Anvendelse af 2-ethylhexyl alfa-cyano-beta, beta-diphenylacrylat med henblik på at forbedre stabiliteten over for lys af p-methylbenzyliden-kamfer
BR9507444A (pt) Processo de preparação de trialcoilsilil 7 bacatina III
DE69816244D1 (de) Verwendung von 2-Aryl-3-aroylbenzo(b)thiophene zur Behandlung des Oestrogenenthaltungssyndroms
HUP0302408A2 (hu) Új aminotriazolon-vegyületek, eljárás ezek előállítására és ezeket tartalmazó gyógyászati készítmények
ATE306271T1 (de) Kombination von loteprednol und beta2- adrenozeptor-agonisten und ihre verwendung durch inhalation zur behandlung von asthma bronchiale
DK1150682T3 (da) Ubichinon Qn til behandling af migrænesmerter
DE502004010950D1 (de) Verwendung von alkyl-oligoglykosidcarboxylaten in mitteln zur behandlung keratinischer fasern
BRPI0409586A (pt) ácidos hidroxámicos úteis no tratamento de distúrbios hiperproliferativos

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees